口服黏菌素联合新霉素对实体器官移植受者多重耐药肠杆菌定植的去污染效果:多中心随机对照试验
多中心、开放标签、平行组随机对照试验纳入105例移植前或移植后肠道定植多重耐药肠杆菌的实体器官移植受者,按1:1分为口服硫酸黏菌素联合硫酸新霉素14天去污染组(53例)与不治疗组(52例)。去污染组多重耐药肠杆菌感染风险未见显著下降(9.4%对13.5%,RR 0.70,95%CI 0.24-2.08,P 0.517)。去污染组出现黏菌素耐药及腹泻等不良反应,需重视。
要点
- 口服黏菌素联合新霉素未显著降低实体器官移植受者多重耐药肠杆菌感染风险。
- 去污染组5.6%出现黏菌素耐药,22.7%发生腹泻,其中15.0%与治疗相关。
- 对多重耐药肠杆菌定植的移植受者,不推荐常规口服去污染以预防感染。
核心结论
- 在实体器官移植受者中,口服黏菌素联合新霉素去污染未能显著降低多重耐药肠杆菌感染风险。
- 去污染组出现黏菌素耐药与腹泻等不良反应,是必须认真对待的潜在问题。
研究设计与样本
- 多中心、开放标签、平行组、1:1随机对照试验,在五个移植中心开展。
- 768例实体器官移植受者接受多重耐药肠杆菌肠道定植筛查,105例定植者入组,去污染组53例、不治疗组52例。
- 去污染方案为硫酸黏菌素联合硫酸新霉素口服14天,主要结局为多重耐药肠杆菌感染诊断,随访至治疗结束后30天,采用意向性分析。
主要发现
- 去污染组多重耐药肠杆菌感染5/53(9.4%),不治疗组7/52(13.5%),差异无统计学意义(RR 0.70;95%CI 0.24-2.08;P 0.517)。
- 去污染组3例(5.6%)、不治疗组1例(1.9%)出现黏菌素耐药,合计4例(5.6%)。
临床怎么用
- 对于多重耐药肠杆菌肠道定植的实体器官移植受者,不应常规使用口服黏菌素联合新霉素去污染来预防感染。
- 临床决策时需权衡去污染可能带来的黏菌素耐药与腹泻等不良反应风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the efficacy of oral colistin-neomycin in preventing multidrug-resistant Enterobacterales (MDR-E) infections in solid organ transplant (SOT) recipients. METHODS: Multicentre, open-label, parallel-group, controlled trial with balanced (1:1) randomization in five transplant units. SOT recipients were screened for MDR-E intestinal colonization (extended-spectrum β-lactamase or carbapenemase producing) before transplantation and +7 and + 14 days after transplantation and assigned 1:1 to receive treatment with colistin sulfate plus neomycin sulfate for 14 days (decolonization treatment (DT) group) or no treatment (no decolonization treatment (NDT) group). The primary outcome was diagnosis of an MDR-E infection. Safety outcomes were appearance of adverse effects, mainly diarrhoea, rash, nausea and vomiting. Patients were monitored weekly until 30 days after treatment. Intention-to-treat analysis was performed. RESULTS: MDR-E rectal colonization was assessed in 768 SOT recipients; 105 colonized patients were included in the clinical trial, 53 receiving DT and 52 NDT. No significant decrease in the risk of infection by MDR-E was observed in the DT group (9.4%, 5/53) compared to the NDT group (13.5%, 7/52) (relative risk 0.70; 95% confidence interval 0.24-2.08; p 0.517). Four patients (5.6%), three (5.6%) in the DT group and one (1.9%) in the NDT group, developed colistin resistance. Twelve patients (22.7%) in the DT group had diarrhoea, eight related to treatment (15.0%); one patient (1.8%) developed skin rash and another (1.8%) nausea and vomiting. Two patients (3.8%) in the NDT group developed diarrhoea. CONCLUSIONS: DT does not reduce MDR-E infections in SOT. Colistin resistance and adverse effects such as diarrhoea are a potential issue that must be taken seriously.
引用
- Fariñas MC, González-Rico C, Fernández-Martínez M, et al. Oral decontamination with colistin plus neomycin in solid organ transplant recipients colonized by multidrug-resistant Enterobacterales: a multicentre, randomized, controlled, open-label, parallel-group clinical trial. Clin Microbiol Infect. 2020. PMID: 33359562. doi:10.1016/j.cmi.2020.12.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。